-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, Hisun Pharmaceutical announced its 2020 results.
Among them, anti-tumor drug revenue was 819 million yuan, the same as in 2019; anti-infection revenue was 2.
In terms of drug registration and approval, the second and third batches of national drugs were selected for centralized procurement of solinacine succinate tablets, glucosamine sulfate capsules, anastrozole tablets, letrozole tablets, and ticagrelor tablets;
A total of 7 varieties have passed the national generic drug consistency evaluation (donepezil hydrochloride orally disintegrating tablets, acarbose tablets, and ticagrelor tablets were approved for production according to the new registration classification 4, and favilavir tablets were produced according to the new registration classification 3 Approval documents, deemed to have passed the consistency evaluation), among which mycophenolate mofetil capsules, donepezil hydrochloride orally disintegrating tablets, and favilavir tablets are the first in China;
A total of 7 preparations and 1 raw material veterinary drug variety have been approved for production; the innovative drug project Hezemibu has submitted supplementary materials, HS234 and HS236 projects have obtained clinical implied permits and started clinical phase I trials, and HS269 projects have completed preclinical studies ; Insulin deglubber has started phase I clinical trials, insulin glargine has completed its prenatal clinical trials, and the insulin aspart injection project has obtained the "Notice of Acceptance" for the marketing application issued by the State Food and Drug Administration.
Progress of Major R&D Projects of Hisun Pharmaceutical
In terms of patents, a total of 34 patent applications (22 domestic applications and 12 PCT international applications) were realized, including 33 invention patents and 1 utility model patent; 48 patents were authorized, including 44 invention patents and 4 design patents .
